Inhaled albuterol/salbutamol and ipratropium bromide and their combination in the treatment of chronic obstructive pulmonary disease

被引:20
作者
Gordon, Joshiah [1 ,2 ]
Panos, Ralph J. [1 ,2 ]
机构
[1] Cincinnati Vet Affairs Med Ctr, Pulm Crit Care & Sleep Div, Cincinnati, OH 45220 USA
[2] Univ Cincinnati, Sch Med, Pulm Crit Care & Sleep Div, Cincinnati, OH 45220 USA
关键词
VENTILATED COPD PATIENTS; METERED-DOSE INHALER; ACUTE MYOCARDIAL-INFARCTION; FLUTICASONE PROPIONATE/SALMETEROL; ANTICHOLINERGIC BRONCHODILATOR; NONNEURONAL ACETYLCHOLINE; ACUTE EXACERBATIONS; RACEMIC ALBUTEROL; BETA(2) AGONISTS; HEART-FAILURE;
D O I
10.1517/17425251003649549
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Importance of the field: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality throughout the world. Combination therapy with albuterol and ipratropium bromide was approved > 15 years ago for the treatment of COPD. We review the mechanism of action, clinical efficacy, and safety of albuterol, ipratropium and combined albuterol-ipratropium therapy. Areas covered in this review: We conducted a PubMed literature search using the keywords COPD, albuterol, ipratropium bromide and Combivent<SU (R)</SU (Boehringer Ingelheim Corp., Ridgefield, CT, USA); pertinent references within the identified citations are included in the review. Data from the manufacturers are also evaluated. What the reader will gain: At the time of its approval, albuterol/ipratropium bromide was an innovative combination of existing medications for the treatment of COPD. The combined formulation provides better improvement in airflow than either component alone and, by reducing the number of separate inhalers, simplifies therapy and improves compliance compared with the individual components. Take home message: The recent development and approval of longer acting and more potent beta agonists, anticholinergics and newer combination treatments have surpassed many of the advantages of combined albuterol-ipratropium for the treatment of patients with stable COPD.
引用
收藏
页码:381 / 392
页数:12
相关论文
共 107 条
[21]   β-adrenoceptor responses of the airways:: For better or worse? [J].
Broadley, KJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 533 (1-3) :15-27
[22]  
[Brunton LL. Goodman and Gilman's Goodman and Gilman's], 2005, PHARM BASIS THERAPEU, V11th
[23]   For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base [J].
Campbell, S .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (02) :156-160
[24]  
Campbell S C, 2000, Respir Care, V45, P864
[25]   Cardiovascular Safety of Tiotropium in Patients With COPD [J].
Celli, Bartolome ;
Decramer, Marc ;
Leimer, Inge ;
Vogel, Ulrich ;
Kesten, Steven ;
Tashkin, Donald P. .
CHEST, 2010, 137 (01) :20-30
[26]   Update on the management of COPD [J].
Celli, Bartolome R. .
CHEST, 2008, 133 (06) :1451-1462
[27]   Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper [J].
Celli, BR ;
MacNee, W ;
Agusti, A ;
Anzueto, A ;
Berg, B ;
Buist, AS ;
Calverley, PMA ;
Chavannes, N ;
Dillard, T ;
Fahy, B ;
Fein, A ;
Heffner, J ;
Lareau, S ;
Meek, P ;
Martinez, F ;
McNicholas, W ;
Muris, J ;
Austegard, E ;
Pauwels, R ;
Rennard, S ;
Rossi, A ;
Siafakas, N ;
Tiep, B ;
Vestbo, J ;
Wouters, E ;
ZuWallack, R .
EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (06) :932-946
[28]   REGULAR USE OF INHALED ALBUTEROL AND THE ALLERGEN-INDUCED LATE ASTHMATIC RESPONSE [J].
COCKCROFT, DW ;
OBYRNE, PM ;
SWYSTUN, VA ;
BHAGAT, R .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1995, 96 (01) :44-49
[29]   REGULAR INHALED SALBUTAMOL AND AIRWAY RESPONSIVENESS TO ALLERGEN [J].
COCKCROFT, DW ;
MCPARLAND, CP ;
BRITTO, SA ;
SWYSTUN, VA ;
RUTHERFORD, BC .
LANCET, 1993, 342 (8875) :833-837
[30]   Standard dose of inhaled albuterol significantly increases QT dispersion compared to low dose of albuterol plus ipratropium bromide therapy in moderate to severe acute asthma attacks in children [J].
Coskun, S ;
Yuksel, H ;
Tikiz, H ;
Danahaliloglu, S .
PEDIATRICS INTERNATIONAL, 2001, 43 (06) :631-636